| Literature DB >> 35073992 |
Mitchell Bestry1, Martyn Symons1,2, Alexander Larcombe3,4, Evelyne Muggli5,6, Jeffrey M Craig6,7,8, Delyse Hutchinson6,7,9,10,11, Jane Halliday6,12, David Martino13,14.
Abstract
BACKGROUND: Prenatal alcohol exposure (PAE) is associated with a range of adverse offspring neurodevelopmental outcomes. Several studies suggest that PAE modifies DNA methylation in offspring cells and tissues, providing evidence for a potential mechanistic link to Fetal Alcohol Spectrum Disorder (FASD). We systematically reviewed existing evidence on the extent to which maternal alcohol use during pregnancy is associated with offspring DNA methylation.Entities:
Keywords: DNA methylation; Epigenetics; Fetal alcohol spectrum disorder; Pregnancy; Prenatal alcohol exposure
Mesh:
Year: 2022 PMID: 35073992 PMCID: PMC8785586 DOI: 10.1186/s13148-022-01231-9
Source DB: PubMed Journal: Clin Epigenetics ISSN: 1868-7075 Impact factor: 6.551
Fig. 1PRISMA flowchart outlining the study selection process across both searches
Summary table of articles included in this systematic review
| First author | Year | Organism | Study type | Scale | Loci (if targeted) | Total sample size | Exposure pattern | Ethanol exposure time (gestational days) | DNA methylation analysis platform | Tissues |
|---|---|---|---|---|---|---|---|---|---|---|
| Wille-Bille | 2020 | Wistar Rats | Intervention | Targeted | 32 | Moderate | GD 17–20 | Pyrosequencing | Ventral Tegmental Area (PDYN), Amygdala (KOR) | |
| Alberry | 2020 | C57Bl/6 Mouse | Intervention | MWAS | - | 21 | Moderate | GD 0–21 | MeDIP-Chip | Hippocampus |
| Abbott | 2018 | CD1 Mouse | Transgenerational | Global + Targeted | 195 | Moderate-high | GD 0.5–19.5 | MSP + ELISA | Rostral & Caudal regions of neocortex | |
| Lussier | 2018 | Sprague–Dawley Rats | Intervention | MWAS | - | 39 | Moderate | GD 1–21 | Bisulfite sequencing | Hippocampus, white blood cells |
| Marjonen | 2018 | C57Bl/6 J Mouse Rcc | Intervention | Targeted | 10 | Moderate | GD 0.5–8.5 | MassARRAY EpiTYPER | Embryonal + placental | |
| Lu | 2018 | Wistar Rats | Intervention | Targeted | 16 | Unclear, possibly high | GD 9–20 | Amplicon sequencing | Hippocampus | |
| Wille-Bille | 2018 | Mouse | Intervention | Targeted | 64 | Moderate | GD 17–20 | MSP | Ventral Tegmental Area, NAc (PDYN only), Prefrontal Cortex (KOR only) | |
| Ozturk | 2017 | C57Bl/6 Mouse | Intervention | Global | - | 18 | Moderate | GD 7–16 | ELISA | Neocortex |
| Zhou | 2016 | C57Bl/6 J Mouse | Intervention | Targeted | Igf2/H19, DMR0, DMR1, DMR2, H19 DMR | 33 | High | GD 0.5–15.5 | MassARRAY EpiTYPER | Heart, brain, placental |
| Zhang | 2015 | C57Bl/6 Mouse | Intervention | Targeted | From -144 to -20 bp | 109 | Moderate | GD 0–8.5 | Bisulfite sequencing | Hippocampus |
| Ngai | 2015 | Sprague–Dawley Rats | Intervention | Targeted | 18 | Unclear | GD 1-? (possibly 20) | Pyrosequencing | Hippocampus, hypothalamus | |
| Marjonen | 2015 | C57Bl/6 J Mouse Rcc | Intervention | Targeted | Six CpG islands in each of | 18 | Moderate | GD 0.5–8.5 | Amplicon sequencing | Hippocampus, main olfactory epithelium |
| Gangisetty | 2015 | Fisher-344 Rats | Intervention | Targeted | 18 | Moderate | GD 7–21 | MSP + pyrosequencing | Pituatry gland | |
| Gangisetty | 2014 | Sprague–Dawley Rats | Intervention | Targeted | 18 | Moderate | GD 7–21 | MSP | Mediobasal hypothalamus | |
| Chen | 2013 | C57Bl/6 Mouse | Intervention | Global | - | 17 | Moderate-high | GD 7–16 | Immunohistochemistry | Hippocampus |
| Laufer | 2013 | C57Bl/6 Mouse | Intervention | MWAS | - | 12 | Unclear | GD 0–10 | MeDIP-Chip | Whole brain |
| Bekdash | 2013 | Sprague–Dawley Rats | Intervention | Targeted | 24 | Moderate | GD 7–21 | MSP | Mediobasal hypothalamus | |
| Govorko | 2012 | Sprague–Dawley Rats | Transgenerational | Global + Targeted | 45 | Moderate | GD 7–21 | MSP + pyrosequencing + Immunohistochemistry | Brain | |
| Downing | 2011 | C57BL/6 J (B6) Mouse | Intervention | Targeted | 45 | High | GD 0–8.5 | Amplicon sequencing | Embryonal + placental | |
| Stouder | 2011 | Normal FVB/N Mouse | Intervention | Targeted | 38 | Light | GD 10–18 | Pyrosequencing + Amplicon Sequencing | Tail, liver, tibialis anterior muscle, hippocampus, whole brain, sperm | |
| Kaminen-Ahola | 2010 | C57Bl/6 Mouse | Intervention | Global + Targeted | A(vy) allele | 373 | Moderate | GD 0.5–8.5 | Bisulfite sequencing | Forebrain, tail |
| Haycock | 2009 | C57Bl/6 & CastEi Hybrid Mouse | Intervention | Targeted | 10 | High | GD 1.5 & 2.5 | Bisulfite sequencing | Embryonal + placental | |
| Murillo-Fuentes | 2005 | Wistar Rats | Intervention | Global | - | 32 | Moderate-high | GD 0–8.5 | Tritiated thymidine incorporation | Blood, liver |
| Maier | 1999 | Harlan Sprague–Dawley Rats | Intervention | Targeted | 9 | High | Unclear, possibly GD 1–20 | Restriction digest + Southern Blot | Olfactory bulbs | |
| Valles | 1997 | Wistar Rats | Intervention | Targeted | 4 | Unclear, possibly moderate | Presumably GD 1–20 | Restriction digest + Southern Blot | Brain | |
| Garro | 1991 | Swiss-Webster Mice | Intervention | Global | - | 164 | High | GD 9–11.5 | Tritiated thymidine incorporation | Fetal |
| Okazaki | 2021 | Human | Case–control study | MWAS | Five epigenetic clocks | 12 | FASD | - | Illumina 450 Beadchip | Buccal, peripheral blood |
| Timms | 2019 | Human | Observational Cohort Study | MWAS | - | 783 | Unclear | Unclear | Illumina 450 Beadchip | Cord blood |
| Cobben | 2019 | Human | Case–control study | MWAS | - | 138 | FASD | - | Illumina 450 Beadchip | Whole blood |
| Sarkar | 2019 | Human | Case–control Study | Targeted | 224 | Moderate-high | Month of conception and/or before birth (study 1), throughout pregnancy (study 2) | MSP + pyrosequencing | Buccal | |
| Lussier | 2018 | Human | Case–control study | MWAS | - | 48 | FASD | - | Illumina 450 Beachchip + pyrosequencing | Buccal |
| Frey | 2018 | Human | Observational Cohort Study | MWAS | - | 156 | Unclear | Last 8 weeks of pregnancy | Illumina 450 Beadchip | Buccal |
| Sharp | 2018 | Human | Meta-analysis | MWAS | - | 3075 | Multiple patterns assessed (low/moderate and binge) | Second/third trimester | Illumina 450 Beadchip | Cord blood |
| Marjonen | 2017 | Human | Case–control study | Targeted | 75 | Moderate-high | Likely throughout | MassARRAY EpiTYPER | Placenta | |
| Portales-Casamar | 2016 | Human | Case–control study | MWAS | - | 206 | FASD | - | Illumina 450 Beachchip + pyrosequencing | Buccal |
| Fransquet | 2016 | Human | Observational Cohort Study | Targeted | 536 | Multiple patterns assessed | Multiple patterns assessed | MassARRAY EpiTYPER | Buccal | |
| Laufer | 2015 | Human | Case–control study | MWAS | - | 23 | FASD | - | Illumina 450 Beachchip + pyrosequencing | Buccal |
| Lee | 2015 | Human | Observational Cohort Study | Targeted | 164 | Multiple patterns assessed (light, moderate and binge) | Likely throughout | Restriction digest + MSP | Cord blood | |
| Masemola | 2015 | Human | Case–control study | Targeted | 533 | FAS | Unclear/likely throughout | Pyrosequencing | Whole blood (all), buccal (cases only) | |
| Azzi | 2014 | Human | Observational Cohort Study | Targeted | 213 | Unclear | Last 3 months of pregnancy | MSP | Cord blood, leukocytes | |
| Jarmasz | 2019 | Human & Macaque Monkeys | Case–control study | Global | - | 36 | Variable | Variable | Immunohistochemistry | Brain |
| Loke | 2018 | Human | Observational Cohort Study | Global | - | 187 | Variable | Multiple patterns assessed | MassARRAY EpiTYPER | Placenta |
Fig. 2Summary chart of risk of bias assessment for human studies. The Percentage of studies scored for each bias domain is shown
Summary table of candidate gene studies assessing DNA methylation in the Igf2/H19 locus
| Publication | Locus | Tissue | Change in methylation from PAE |
|---|---|---|---|
| Marjonen (2017) | H19 DMR (C6), H19 ICR | Placenta | Hypomethylation (nominal P-value only) |
| Masemola | H19 ICR (C6) | Blood, buccal | Hypomethylation |
| Marjonen (2018) | H19 ICR (C1 and C2), IGF2 DMR1 | Placenta, embryo | No change |
| Haycock | H19 ICR (C1 and C2) | Placenta, embryo | Hypomethylation in placenta, no change in embryo |
| Zhou | H19 DMR, IGF2 DMR0, 1,2 | Heart, brain, placenta | Hypomethylation at Igf2 DMR1, Igf2 DMR2, and H19, no change at Igf2 DMR0 |
| Downing | IGF2 DMR1 | Placenta, embryo | Hypomethylation |
| Stouder | H19 ICR | Sperm, brain, muscle, liver, tail | Hypomethylation in CTCF12 (F1) and all six sites (F2) in sperm, no change in other tissues (F1) |